Daiichi Sankyo
Alix Poeton is an experienced professional in the field of oncology market access and pricing, currently serving as Director of Global Oncology Market Access & Pricing at Daiichi Sankyo, Inc. since January 2021, and previously held the position of Associate Director in the same department. Prior to this role, Alix was with AstraZeneca from October 2018 to January 2021 as Sr. Manager of Oncology Access Strategy in the U.S. Additionally, experience includes a tenure at ICON plc from October 2013 to September 2018, where various roles in Pricing & Market Access were held, progressing from Senior Analyst to Lead Consultant. Early career includes work as a Pricing & Market Access Analyst at KnowledgePoint360 Group from January 2012 to June 2013. Alix Poeton holds a B.A. in International Business & Management from Dickinson College, earned between 2008 and 2012.
This person is not in any teams
This person is not in any offices
Daiichi Sankyo
21 followers
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Daiichi Sankyo Group and Ranbaxy Group. The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.